version updat model
reflect dental ipo pend ge deal
updat estim new new
follow recent ipo envista dental busi
non-control interest ahead expect close transform
ge life scienc acquisit updat model overal ebitda estim
increas rais updat estim
share trade ev/ebitda in-lin tool peer group averag
howev see dhr acceler organ growth rate revenu mix end-market
exposur attract life scienc tool group justifi
premium valuat po equat multipl ev/ebitda
estim reiter buy rate
well-posit pois higher growth
littl three year follow spin success
transform busi core growth compani one grow
better see chart chart ge footprint
bioprocess one fastest growth area life scienc see recent
bioprocess review molecular diagnost busi cepheid broader
portfolio consum use biopharma research develop via phenomenex
acquisit major acquisit past year target
fastest growth area life scienc diagnost acceler core
perform see continu runway sector time come
move piec debt rais fx time close/spin
updat model account upcom close ge deal
recent first step dental separ acknowledg much uncertainti
remain estim weve taken conserv approach
number signific variabl remain specif time addit debt
rais ie alreadi rais earli septemb usd-
denomin rais earli fund ge transact well actual deal
close current model end also expect exit stake
point model time
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
one largest diversifi
product includ analyt instrument
consum life scienc research
diagnost dental instrument consum
equip servic use water qualiti
test product identif compani
known lead brand across mani
vertic strong manag team
record superior execut
follow juli spin-off industrial-
theme remainco becom one
premier stand-alon life scienc compani
well-posit deliv solid organ
growth benefit favor exposur
stream upsid pall corp
opportun option drive ep
growth mid-teen next sever
chart revenu mix pro forma pall acquisit
chart revenu mix pro forma
po base approxim ev/ebitda support
dcf analysi assum wacc termin growth rate multipl
premium compani lst broader healthcar peer group line
five year histor valuat believ justifi given margin-
expans potenti opportun capit deploy superior manag team
strong track record exist industri investor base
downsid risk po fx risk econom risk cyclic exposur reduct
 fund custom consolid slow bioprocess demand competit
risk risk pend acquisit complet
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
